As of 2024-12-11, the EV/EBITDA ratio of Medincell SA (MEDCL.PA) is -28.21. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MEDCL.PA's latest enterprise value is 539.23 mil EUR. MEDCL.PA's TTM EBITDA according to its financial statements is -19.12 mil EUR. Dividing these 2 quantities gives us the above MEDCL.PA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.4x - 8.2x | 7.3x |
| Forward P/E multiples | 7.2x - 8.2x | 7.7x |
| Fair Price | (6.06) - (6.71) | (6.26) |
| Upside | -135.4% - -139.3% | -136.6% |
| Date | EV/EBITDA |
| 2024-12-06 | -27.69 |
| 2024-12-05 | -27.63 |
| 2024-12-04 | -27.50 |
| 2024-12-03 | -27.38 |
| 2024-12-02 | -27.29 |
| 2024-11-29 | -29.77 |
| 2024-11-28 | -29.37 |
| 2024-11-27 | -29.74 |
| 2024-11-26 | -29.71 |
| 2024-11-25 | -29.13 |
| 2024-11-22 | -28.70 |
| 2024-11-21 | -28.30 |
| 2024-11-20 | -28.36 |
| 2024-11-19 | -28.06 |
| 2024-11-18 | -27.63 |
| 2024-11-15 | -28.76 |
| 2024-11-14 | -29.28 |
| 2024-11-13 | -29.43 |
| 2024-11-12 | -29.40 |
| 2024-11-11 | -30.20 |
| 2024-11-08 | -29.49 |
| 2024-11-07 | -28.97 |
| 2024-11-06 | -26.86 |
| 2024-11-05 | -25.46 |
| 2024-11-04 | -25.58 |
| 2024-11-01 | -25.36 |
| 2024-10-31 | -24.97 |
| 2024-10-30 | -25.46 |
| 2024-10-29 | -25.06 |
| 2024-10-28 | -24.78 |
| 2024-10-25 | -25.09 |
| 2024-10-24 | -25.00 |
| 2024-10-23 | -25.79 |
| 2024-10-22 | -26.19 |
| 2024-10-21 | -26.22 |
| 2024-10-18 | -25.98 |
| 2024-10-17 | -25.52 |
| 2024-10-16 | -25.52 |
| 2024-10-15 | -26.56 |
| 2024-10-14 | -26.04 |
| 2024-10-11 | -25.30 |
| 2024-10-10 | -25.00 |
| 2024-10-09 | -25.33 |
| 2024-10-08 | -25.46 |
| 2024-10-07 | -25.55 |
| 2024-10-04 | -25.40 |
| 2024-10-03 | -25.24 |
| 2024-10-02 | -25.76 |
| 2024-10-01 | -25.70 |
| 2024-09-30 | -26.04 |